[{"id":"c585fc8f-5ca9-4ccf-af6f-4cb8e94745d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861895","created_at":"2023-05-17T14:05:15.792Z","updated_at":"2024-07-02T16:35:26.123Z","phase":"Phase 1","brief_title":"A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors","source_id_and_acronym":"NCT05861895","lead_sponsor":"HighField Biopharmaceuticals Corporation","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HF158K1"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 04/23/2025","primary_completion_date":" 04/23/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2023-12-15"}]